<DOC>
	<DOCNO>NCT02461043</DOCNO>
	<brief_summary>Esophageal cancer highly aggressive malignancy poor overall outcome . - Five year survival rate radical esophagectomy modest 40 % .The patient regional lymph node metastasis worse outcome without lymph node metastasis . - No standard postoperative adjuvant chemotherapy ever establish .</brief_summary>
	<brief_title>Adjuvant Chemotherapy With Paclitaxel Cisplatin Lymph Node-Positive Adjuvant Chemotherapy Treatment Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>ability give inform consent histological proof thoracic esophageal squamous cell carcinoma negative proximal distal margin nodepositive pathologic stage M0 Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Patients enrol 4 10 week surgery Adequate organ function require 2 week registration define : serum creatinine within normal institutional limit , creatinine clearance ( CrCl ) ≥60ml/minute . Aspartate aminotransferase bilirubin＜2 time upper normal institutional limit prior chemotherapy concurrent radiation therapy esophagectomy R1 R2 resection clinically significant hearing loss symptomatic peripheral neuropathy initial examination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>adjuvant chemotherapy</keyword>
	<keyword>esophageal surgery</keyword>
	<keyword>paclitaxel</keyword>
</DOC>